Dr. Xiang is an accomplished drug hunter with over 20 years experience in discovery and development of therapeutics for oncology, autoimmune and metabolic disease. Dr. Xiang experience spans multiple therapeutic modalities including small molecules, antibody-drug conjugates as well as bifunctional protein degraders (PROTACs). Dr. Xiang led preclinical and development program teams that led to multiple clinical products including three commercial products. Prior to founding Polymed, Dr. Xiang led the research and development team at Suzhou Kintor (HKG:9939) as Chief Technology Officer. Dr. Xiang also led Chemistry at ChemPartners as the Vice President for 6 years. Dr. Xiang started his career at Wyeth Pharmaceuticals (now part of Pfizer Inc), where he led a number of preclinical drug discovery teams during his 13 yr career. Dr. Xiang has received numerous awards such as Monsanto Outstanding Research Award, Abbott Excellent Organic Research Award, Wyeth Clinical Candidate Award and 2017 Shanghai Small Business Innovation Award. He published 63 publications in top-tier journals and 18 Issued patents. In addition to his scientific acumen, Dr. Xiang is a proven goal-oriented business leader and has developed business strategy, raised funds for early stage ventures and executed on strategic collaborations with large pharma, biotech, venture and academic partners.

Dr, Wang joins Polymed with more than 20 years of diverse experience in research, drug discovery and development across a wide spectrum of therapeutic areas including autoimmune diseases, cancer and diabetes for small molecule, peptide and biological drug candidates. During her 13 years at Wyeth (which later became Pfizer), where she was a project leader for many multidisciplinary teams, Dr. Wang and her group supported numerous preclinical and clinical stage projects from target identification, HTS assay development, lead characterization, and mechanism of action evaluation of drug targets such as enzymes, GPCRs and nuclear receptors. Dr. Wang received several awards including the Wyeth Above and Beyond Award. Later at multiple biotech startups, Dr. Wang served as director of biology, led the team of many major projects range from preclinical to clinical stage II trials. She was also the key contributor to the development of label-free assay platforms for ion channels and transporters using x-ray fluorescence technology. This project was able to be successfully moved from start to CRO service within a very short time. Dr. Wang received her B.S. in Microbiology from Fundan Univerity and her Ph.D. in biochemistry from North Texas University. Dr. Wang completed her postdoctoral training at Harvard Medical School. Dr. Wang has published more than 30 papers in high-impact journals such as Cell and Cell Biology.

Dr. He Zhou: Senior Vice President and Chief Operation Officer Dr, Zhou is a seasoned industry veteran with 20+ years of experience in preclinical/clinical drug development, and management. Prior to joining Polymed, Dr. Zhou served as Head of Oncology Pharmacology at Momenta Pharmaceuticals (a wholly-owned subsidiary of Johnson & Johnson), Head of Oncology Pharmacology and Executive Director at Shanghai ChemPartner, Senior Director in Clinical Biomarker at BeiGene, China General Manager and VP at HiFiBiO Therapeutics, Head of Research and VP at Beijing Migrasome Therapeutics. She led multiple projects, including 5 (3 antibodies, a small molecule, and a carbohydrate) as a core member through screening to successful IND filing, with 10+ drug candidates entering clinical trials, 3 approved and marketed. With her medical training, she also participated in multiple Phase I-III clinical trials in US and China, led and completed 1 Phase I clinical trial in China. Dr. Zhou received her B.S. in Medicine and a M.S. in Immunology from Peking University Health Science Center (formerly Beijing Medical University) and her Ph.D. in Immunology from University of Mississippi Medical Center. She completed her postdoctoral training in Immuno-Oncology in Dr. Ralph Reisfeld’s laboratory at The Scripps Research Institute. She has published 40 research articles in high-impact journals such as Cancer Cell and Nature Communications, and 6 issued patents.

Dr. Zhijian Lu is a skilled leader with in-depth knowledge and extensive experience in biotherapeutic research and development. He has an established track record working in cross functional teams to overcome technical and strategic issues for biotherapeutic pipeline projects. Dr. Lu’s drug discovery career started in Genetics Institute, where his researches were in the areas of peptide display, cytokine structure/function studies, and signal transduction/functional proteomics. After Genetics Institute was integrated into Wyeth in the late 90's, Dr. Lu's focus shifted to the discovery of biotherapeutics including recombinant proteins and monoclonal antibodies. He led a number of technology platforms for biotherapeutic discovery, and managed protein drug projects from hit generation and to candidate selection. After Wyeth became part of Pfizer, Dr. Lu's responsibility also included exploring potential collaborations in Asia Pacific area for novel methods used in biotherapeutic discovery. In 2011 Dr. Lu joined Novartis to lead its biologics discovery unit in Shanghai where he worked for 5 years. As part of the global NIBR organization, the unit worked with disease areas such as Oncology, Immunology, Respiratory Diseases, Infectious Disease and Ophthalmology to create novel biotherapeutics. Dr Lu is seasoned manager for developing talents and building high performing teams. Dr. Zhijian Lu’ scientific trainings included protein biochemistry studies in Dr. Richard Laursen’s lab for PhD degree, and the post-doctoral research in Dr. Gobind Khorana’s lab at MIT on structure-function relationship of rhodopsin.